Skip Content

Featured news

Some very sad news

The A-T Society is shocked and deeply saddened to learn that fundraiser Kevin Kennedy, who was enthusiastically preparing to ride the RideLondon 100 on behalf of the A-T Society, collapsed and died while out training for the event on Sunday.

Kevin, who was 48, was part of a group of six friends from Rickmansworth who had been training together since February for the 100 mile challenge event. He was married with two teenage sons. Like most of the group he had not been an active cyclist before taking it up again to raise funds for the Society. But he had thrown himself into the project with real gusto.

The thoughts and prayers of the A-T Society are with Kevin's wife and family.

EryDex studies gain FDA approval

Good news from the USA. The company EryDel has been granted permission by the US Food and Drugs Administration (FDA) to proceed with tests on its innovative Erydex system for delivering dexamethasone.

As we reported a few weeks ago, FDA authorisation will result in the need for some small phase 1 (safety) trials, before moving onto a bigger trial, which will be critical in determining the drug’s effectiveness. This trial will take place in several different countries and is likely to include patients in the UK.

Shop online Research into AT

A-T Society News, Jan 2013

 cover of Jan 2013 edition of A-T Society News

The latest edition of the Society's newsletter, its cover graced by Emily Woodward meeting Ade Adepitan, features interviews with South African paralympic cyclist Roxy Burns and Israeli researcher Yossi Shiloh.

In addition, you will find news from the A-T Neuroscience Forum in Washington in November, an introduction to our two new celebrity Patrons, updates on research and benefits, stories from our amazing fundraisers and much more .

 

Learn more

New diagnosis